

Restriction to one of the following inventions has been required under 35 USC 121:

I to VI. Claims 1-2, in so far as they are drawn to **any one** of the six biopolymer marker sequences recited therein, classified in class 530, subclass 300. For example, Invention I consists of claims 1-2 only in so far as they encompass a biopolymer marker of SEQ ID NO: 1. Invention VI consists of claims 1-2 only in so far as they encompass a biopolymer marker of SEQ ID NO: 6.

VII to XIII. Claims 3-9, in so far as they are drawn to a method for evidencing a disease by evidencing any one of six biopolymer marker sequences, classified in class 424, subclass 86, for example.

XIV to XX. Claims 10-28, in so far as it is drawn to a diagnostic kit comprising a material capable of binding to any one of six biopolymer markers, classified in class 424, subclass 130.1, for example.

XXI to XXVII. Claims 29-32, in so far as they are drawn to an antibody that binds to any one of six biopolymer markers, classified in class 530, subclass 397.1, for example.

XXVIII to XXXIV. Claims 33-37, in so far as they are drawn to a process for identifying therapeutic avenues by using any one of six biopolymer markers, classified in class 435, subclass 7.1, for example.

XXXV to XLII. Claim 38, in so far as they are drawn to a process for regulating a disease state by controlling the presence or absence of any one of six biopolymer markers, classified in class undetermined, subclass undetermined, for example.

Applicants here elect with traverse Group I (claims 1 and 2 as drawn to SEQ ID NO:1) for prosecution on the merits.

It is noted that the Examiner has also required an election of species under 35 U.S.C. 121 for Groups VII-XX, however since Applicants elect Group I as drawn to SEQ ID NO:1, the election of species is considered to be non-applicable.